Neural Regeneration Research ›› 2024, Vol. 19 ›› Issue (6): 1189-1190.doi: 10.4103/1673-5374.385865

Previous Articles     Next Articles

Empagliflozin reduces brain pathology in Alzheimer’s disease and type 2 diabetes

Carmen Hierro-Bujalance, Monica Garcia-Alloza*#br#   

  1. Division of Physiology, School of Medicine, Universidad de Cadiz, Cadiz, Spain (Hierro-Bujalance C, Garcia-Alloza M)
    Instituto de Investigacion e Innovacion en Ciencias Biomedicas de la Provincia de Cadiz (INIBICA), Cadiz, Spain (Hierro-Bujalance C, Garcia-Alloza M)
    Salus Infirmorum-Universidad de Cadiz, Cadiz, Spain (Hierro-Bujalance C)
  • Online:2024-06-15 Published:2023-11-17
  • Contact: Monica Garcia-Alloza, PhD, monica.garcia@uca.es.
  • Supported by:
    This work was supported by Spanish Ministry of Science, Innovation and Universities (grant number PID2020-115499RB-I00/ AEI / 10.13039/501100011033); Andalusian Consejería de Universidad, Investigación e Innovación (PAIDI2020) (grant P20-00928) (to MGA).

PDF

37

Abstract: Alzheimer’s disease (AD) and type 2 diabetes (T2D): More than 55 million people suffer from dementia, and it is expected that over 150 million people will suffer from this disease by 2050. AD is the most common type of dementia and while aging remains the main risk factor to suffer it, previous studies have also shown that metabolic disorders, and T2D specifically, are also major contributors (Wang et al., 2012). The prevalence of diabetes has reached 537 million people worldwide and these figures are expected to keep rising (Ahmad et al., 2022). All things considered, both diseases are a great challenge for health professionals as well as a major social problem.